Curasight AS (FRA:CUS) Short-term investments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:CUS Curasight AS FRA:CUS
19 GF Score
Price €2.19
! 2 Warning Signs
View Full Analysis

What is Curasight AS Short-term investments?

Short-term investments only applies to insurance companies.

FRA:CUS
19GF Score
Curasight AS FRA:CUS
Short-term investments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Curasight AS Business Description

Other Exchanges CURAS:Sweden
Address Ole Maaloes Vej 3, Kobenhavn N, Kobenhavn, DNK, DK-2200
Curasight AS is a clinical-stage radiopharmaceutical company based in Copenhagen, Denmark, developing uTREAT, a first-in-class uPAR-targeted radioligand therapy (RLT) platform designed to treat aggressive solid tumors. The Company is focused on advancing its diagnostic and therapeutic platforms through key clinical milestones.
19GF Score

Get the complete analysis for FRA:CUS

Short-term investments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.19
Price